

DATE: Thursday, March 21, 2002

Set Name side by side		Hit Count	Set Name result set
DB=US	SPT,PGPB; PLUR=YES; OP=ADJ		
L11	110 and 17	1	L11
L10	(dna or cdna or nucleic acid or polynucleotide) and 19	4	L10
L9	(corynebacteria or corynebacteria glutamicum) and 18	4	L9
L8	Methyltetrahydrofolate homocysteine methyltransferase or Methionine synthase or Methionine synthetase	73	L8
L7	16 or 15 or 14 or 13 or 12 or 11	13523	L7
L6	(((536/23.2)!.CCLS.))	3444	L6
L5	(((435/320.1)!.CCLS.))	10692	L5
L4	(((435/252.32)!.CCLS.))	110	L4
L3	(((435/252.3)!.CCLS.))	5269	L3
L2	(((435/193)!.CCLS.))	813	L2
L1	((435/183)!.CCLS.)	1248	L1

END OF SEARCH HISTORY

End of Result Set

Generate Collection Print

L11: Entry 1 of 1

File: USPT

PA

Feb 19, 2002

US-PAT-NO: 6348328

DOCUMENT-IDENTIFIER: US 6348328 B1

TITLE: Compounds

DATE-ISSUED: February 19, 2002

INVENTOR - INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Black; Michael Terence Chester Springs PA Hodgson; John Edward Malvern PA

Knowles: David Justin

Charles Boroughbridge GBX

Nicholas; Richard Oakley Collegeville

Stodola; Robert King Flourtown PA

ASSIGNEE-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY TYPE CODE

SmithKline Beecham Philadelphia PA 02
Corporation

SmithKline Beecham GBX 03

plc. GBX 03

APPL-NO: 8/ 858207 [PALM] DATE FILED: May 14, 1997

INT-CL: [7] C12 P 21/02

US-CL-ISSUED: 435/69.1; 435/320.1, 435/252.3, 536/23.1, 536/23.7 US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 536/23.1, 536/23.7

FIELD-OF-SEARCH: 536/23.4, 536/23.2, 536/23.7, 536/23.1, 435/253.3, 435/252.35, 435/320.1, 435/69.1

PRIOR-ART-DISCLOSED:

U.S. PATENT DOCUMENTS

Search Selected Search ALL

PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
5753480	May 1998	Lawlor	435/183
5756330	May 1998	Lawlor	435/183
<u>5863777</u>	January 1999	Lawlor	435/183

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO

PUBN-DATE

COUNTRY

US-CL

9610647

April 1996

XOW

OTHER PUBLICATIONS

Critical Synergy: The Biotechnology Industry and Intellectual Property Protection, Biotechnology Industry Organization, Washington, D.C., 1994, pp. 75 and 100-107.

ART-UNIT: 1632

PRIMARY-EXAMINER: Martinell; James

ATTY-AGENT-FIRM: Gimmi; Edward R. Deibert; Thomas S. King; William

ABSTRACT:

This invention relates to newly identified polynucleotides. polypeptides encoded by such polynucleotides, the uses of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides and recombinant host cells transformed with the polynucleotides. This invention also relates to inhibiting the biosynthesis or action of such polynucleotides or polypeptides and to the use of such inhibitors in therapy.

22 Claims, 0 Drawing figures

Generate Collection Print

Search Results - Record(s) 1 through 4 of 4 returned.

1. Document ID: US 6348328 B1

L10: Entry 1 of 4

File: USPT

Feb 19, 2002

US-PAT-NO: 6348328

DOCUMENT-IDENTIFIER: US 6348328 B1

TITLE: Compounds

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMIC Draw, Desc | Image

2. Document ID: US 6228983 B1

L10: Entry 2 of 4

File: USPT

May 8, 2001

US-PAT-NO: 6228983

DOCUMENT-IDENTIFIER: US 6228983 B1

TITLE: Human respiratory syncytial virus peptides with

antifusogenic and antiviral activities



3. Document ID: US 6017536 A

L10: Entry 3 of 4 File: USPT

Jan 25, 2000

US-PAT-NO: 6017536

DOCUMENT-IDENTIFIER: US 6017536 A

TITLE: Simian immunodeficiency virus peptides with antifusogenic

and antiviral activities

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw Desc Image

4. Document ID: US 5872104 A

L10: Entry 4 of 4 File: USPT


Feb 16, 1999

US-PAT-NO: 5872104

DOCUMENT-IDENTIFIER: US 5872104 A

TITLE: Combinations and methods for reducing antimicrobial

resistance



Display Format: - Change Format

Previous Page Next Page

=>.d, his (FILE 'HOME' ENTERED AT 14:10:14 ON 21 MAR 2002) FILE 'REGISTRY' ENTERED AT 14:10:21 ON 21 MAR 2002 L11 S 9033-23-2/RN FILE 'HCAPLUS' ENTERED AT 14:13:37 ON 21 MAR 2002 FILE 'REGISTRY' ENTERED AT 14:13:46 ON 21 MAR 2002 SET SMARTSELECT ON L2 SEL L1 1- CHEM: 15 TERMS SET SMARTSELECT OFF FILE 'HCAPLUS' ENTERED AT 14:13:47 ON 21 MAR 2002 L3884 S L2 0 S L3 (L) (CORYNEBACTERIA OR CORYNEBACTERIA GLUTAMICUM)

80 S L5 AND PD<20000802

93 S L3 (L) (DNA OR CDNA OR NUCLEIC ACID OR POLYNUCLEOTIDE)

L4

L5L6

=> d ibib ab 1-12 L6 ANSWER 1 OF 80 HCAPLUS COPYRIGHT 2002 ACS 2001:94757 HCAPLUS ACCESSION NUMBER: DOCUMENT NUMBER: 135:176324 TITLE: Embarking on rice functional genomics via cDNA microarray: use of 3' UTR probes for specific gene expression analysis Yazaki, Junshi; Kishimoto, Naoki; Nakamura, Keiko; AUTHOR(S): Fujii, Fumiko; Shimbo, Kanako; Otsuka, Yoshimi; Wu, Jianzhong; Yamamoto, Kimiko; Sakata, Katsumi; Sasaki, Takuji; Kikuchi, Shoshi CORPORATE SOURCE: Institute of the Society for Techno-innovation of Agriculture, Forestry and Fisheries, Tsukuba, 305-0854, Japan SOURCE: DNA Research (2000), 7(6), 367-370 CODEN: DARSE8; ISSN: 1340-2838 PUBLISHER: Universal Academy Press Journal DOCUMENT TYPE: LANGUAGE: English EST mapping anal. revealed that primers designed from the 3' portion (3'-UTR) of rice ESTs were more gene specific than that from the 5' portion. This observation suggests that the full-length EST insert is effective for comprehensive anal. of family gene expression while the 3'-UTR probe is useful for detecting gene-specific expression. In the full-insert microarray, the ten most highly expressed genes consist of five ubiquitin homologs, two unknown genes and one homolog each of S-adenosyl methionine synthase, NADH dehydrogenase and actin. In the 3'-UTR microarray, three ubiquitin homologs, four unknown genes and one homolog each of thioredoxin, phenylalanine ammonia-lyase and methyltransferase showed the highest signals. Only three ubiquitin homologs and two unknown genes, however, were highly expressed in both full-insert and 3'-UTR microarrays. A 3'-UTR microarray is effective in detecting specific genes in target RNA from various tissues and at different developmental stages. A rice cDNA microarray with approx. 9000 ESTs were constructed. Information on the cDNA clones including identity and accession no. can be accessed at http://microarray.rice.dna.affrc. go.jp/. REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 2 OF 80 HCAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2001:35443 HCAPLUS DOCUMENT NUMBER: 134:365268 TITLE: Co-morbidity of 5,10-methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms and risk for neural tube defects AUTHOR(S):Johanning, Gary L.; Tamura, T.; Johnston, Kelley E.; Wenstrom, Katharine D. CORPORATE SOURCE: Department of Nutrition Sciences, The University of Alabama at Birmingham, Birmingham, AL, 35294-3360, USA SOURCE: Journal of Medical Genetics (2000), 37(12), 949-951 CODEN: JMDGAE; ISSN: 0022-2593 PUBLISHER: BMJ Publishing Group DOCUMENT TYPE: Journal LANGUAGE: English Neural tube defects (NTD5) are among the most common and devastating birth defects. The gene for human methionine synthase (MS), which catalyzes the reaction to form methionine from homocysteine, has recently been cloned, and a common polymorphism has also been identified.

Neural tube defects (NTD5) are among the most common and devastating birth defects. The gene for human methionine synthase (MS), which catalyzes the reaction to form methionine from homocysteine, has recently been cloned, and a common polymorphism has also been identified. Although MS plays an important role in homocysteine metab., this polymorphism has not been reported to be a risk factor for NTD formation, and, to our knowledge, comorbidity of MTHFR and MS polymorphisms for NTDs has never been evaluated. We detd. MTHFR and MS genotypes using DNA isolated from amniotic fluid cells of fetuses with NTDs and of those without any apparent malformations, and evaluated potential assocns.

between polymorphisms in these two genes as a risk factor for the development of NTDs. To our knowledge, this is the first reported study of interactions between frequently occurring polymorphisms of two genes involved in folate metab. We did not find strong assocns. between MTHFR and MS polymorphisms and the risk of NTDs.

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 80 HCAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2001:13837 HCAPLUS

DOCUMENT NUMBER: 135:223334

TITLE: Methionine synthase, a gene required for methionine

synthesis, is expressed in planta by Cladosporium

fulvum

AUTHOR(S): Solomon, Peter S.; Nielsen, Peter Stein; Clark,

Anthony J.; Oliver, Richard P.

CORPORATE SOURCE: Department of Physiology, Carlsberg Laboratory, Valby,

DK-2500, Den.

SOURCE: Molecular Plant Pathology (2000), 1(5),

315-323

CODEN: MPPAFD; ISSN: 1464-6722

PUBLISHER: Blackwell Science Ltd.

DOCUMENT TYPE: Journal LANGUAGE: English

AB The nutritional requirements of phytopathogenic fungi growing in planta has to date been largely ignored. We have begun to address this problem by investigating the methionine requirement for the biotrophic pathogen of tomato Cladosporium fulvum during infection. The Met6 gene from Cladosporium fulvum encoding a cobalamin-independent 5-methyltetrahydropteroyltriglutamate-homocysteine methyltransferase, was cloned by functional yeast complementation. The open reading frame was found to be 2304 bp, contg. no introns and encoding a protein of 87 kDa. In vitro Northern anal. demonstrated high levels of Met6 expression in the absence of externally supplied methionine. However in the presence of methionine or in the absence of carbon, expression of Met6 decreased significantly. Anal. of Met6 expression in planta revealed a strong increase during infection suggesting the requirement for methionine synthesis in planta by Cladosporium fulvum. This study demonstrates that Cladosporium fulvum is starving for methionine during infection and thus

implies the essentiality of primary biosynthetic pathways to the infecting fungus.

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 80 HCAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2000:886027 HCAPLUS

DOCUMENT NUMBER: 134:309023

TITLE: Reduced mRNA abundance of the main enzymes involved in

methionine metabolism in human liver cirrhosis and

hepatocellular carcinoma

AUTHOR(S): Avila, Matias A.; Berasain, Carmen; Torres, Luis;

Martin-Duce, Antonio; Corrales, Fernando J.; Yang, Heping; Prieto, Jesus; Lu, Shelly C.; Caballeria,

Juan; Rodes, Juan; Mato, Jose M.

CORPORATE SOURCE: Division de Hepatologia y Terapia Genica, Departmento

de Medicina Interna, Universidad de Navarra, Pamplona,

31008, Spain

SOURCE: Journal of Hepatology (2000), 33(6), 907-914

CODEN: JOHEEC; ISSN: 0168-8278

PUBLISHER: Munksgaard International Publishers Ltd.

DOCUMENT TYPE: Journal LANGUAGE: English

AB It has been known for at least 50 yr that alterations in methionine metab. occur in human liver cirrhosis. However, the mol. basis of this alteration is not completely understood. To gain more insight into the mechanisms behind this condition, mRNA levels of methionine adenosyltransferase (MATIA), glycine methyltransferase (GNMT),

methionine synthase (MS), betaine homocysteine methyltransferase (BHMT) and cystathionine .beta.-synthase (CBS) were examd. in 26 cirrhotic livers, five hepatocellular carcinoma (HCC) tissues, and ten control livers. The expression of the above-mentioned genes was detd, by guant. RT-PCR anal. Methylation of MAT1A promoter was assessed by methylation-sensitive restriction enzyme digestion of genomic DNA. When compared to normal livers MAT1A, GNMT, BHMT, CBS, and MS mRNA contents were reduced in liver cirrhosis. Interestingly, MAT1A promoter was hypermethylated in the cirrhotic liver. HCC tissues also showed decreased mRNA levels of these enzymes. Thus, the abundance of the mRNA of the main genes involved in methionine metab. is markedly reduced in human cirrhosis and HCC. Hypermethylation of MAT1A promoter could participate in its reduced expression in cirrhosis. These observations help to explain the hypermethioninemia, hyperhomocysteinemia and reduced hepatic glutathione content obsd. in cirrhosis.

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 5 OF 80 HCAPLUS COPYRIGHT 2002 ACS Ь6 ACCESSION NUMBER: 2000:858338 HCAPLUS

DOCUMENT NUMBER: 134:278671

TITLE: Methyl group metabolism gene polymorphisms and

susceptibility to prostatic carcinoma

Kimura, Fumihiro; Franke, Knut H.; Steinhoff, AUTHOR(S):

Christine; Golka, Klaus; Roemer, Hermann C.;

Anastasiadis, Aristoteles G.; Schulz, Wolfgang A.

CORPORATE SOURCE: Urologische Klinik, Heinrich Heine Universitat,

Dusseldorf, D-40225, Germany Prostate (New York) (2000), 45(3), 225-231 SOURCE:

CODEN: PRSTDS; ISSN: 0270-4137

Wiley-Liss, Inc. PUBLISHER:

DOCUMENT TYPE: Journal LANGUAGE: English

Alterations of DNA methylation are very frequent in prostatic AB carcinoma. A possible cause underlying altered DNA methylation could be an insufficient level of S-adenosylmethionine as a consequence of nutritional imbalances or of weaker alleles of genes for its synthesis, i.e., encoding methylene-tetrahydrofolate reductase (MTHFR), methionine synthase (MS), and .beta.-cystathionine synthetase (CBS). Therefore, homozygosity or heterozygosity for such weaker alleles may underlie susceptibility to prostatic carcinoma. The distribution of the two most frequent MTHFR, MS, and CBS alleles was detd. in 132 prostatic carcinoma patients and 150 population controls by restriction fragment length polymorphism-(RFLP) PCR. In the controls, a Hardy-Weinberg equil. was obsd. for each allele pair. No significant differences were obsd. with respect to age or gender. No significant differences for single genes or combinations were found between prostatic carcinoma patients and controls, although the MTHFR Val allele was slightly overrepresented among the tumor patients. Neither did the allele distribution significantly differ among the prostatic carcinoma patients stratified according to age, clin. stage, or presence of metastases. However, the MTHFR Val allele tended to be assocd. with higher tumor grade. In general, the data do not support the hypothesis that weaker alleles in Me group metab. genes constitute a major factor in the high prevalence of DNA methylation alterations found in prostatic carcinoma. However, a potential assocn. with the MTHFR genotype deserves further study.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 6 OF 80 HCAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2000:812999 HCAPLUS

DOCUMENT NUMBER: 135:1051

TITLE: Analysis of the methionine biosynthetic pathway in the

extremely thermophilic eubacterium Thermus

thermophilus

AUTHOR(S): Kosuge, Takehide; Gao, Dai; Hoshino, Takayuki CORPORATE SOURCE: Institute of Applied Biochemistry, University of

Tsukuba, Tsukuba, 305-8572, Japan

SOURCE: Journal of Bioscience and Bioengineering (2000

), 90(3), 271-279

CODEN: JBBIF6; ISSN: 1389-1723

PUBLISHER: Society for Bioscience and Bioengineering, Japan

DOCUMENT TYPE: Journal LANGUAGE: English

AB Four DNA fragments that could rescue the mutations of four Metmutants were cloned from Thermus thermophilus HB27 and their complete nucleotide sequences were detd. Two of the four fragments resp. contained the greater parts of the metF and metH genes, the predicted amino acid sequences of which showed identities of 30.8% and 32.7% with 5,10-methylenetetrahydrofolate reductase (E.C. 1.7.99.5) and vitamin B12-dependent homocysteine transmethylase (E.C.

2.1.1.13) of Escherichia coli. The

other two DNA fragments, which overlapped one another, contained two open reading frames whose predicted amino acid sequences were resp. similar to those of O-acetylhomoserine sulfhydrylase (E.C. 4.2.99.10, the product of the MET17 gene) and homoserine O-acetyltransferase (E.C. 2.3.1.31, the product of the MET2 gene) of Saccharomyces cerevisiae. The metF, metH, MET2, and MET17 genes of T. thermophilus were disrupted by introducing the heat-stable kanamycin nucleotidyltransferase gene into the genome. Each transformant showed methionine auxotrophy. Both the MET2-and MET17-disrupted mutants could grow in a minimal medium contg. homocysteine but not in the same medium contg. succinylhomoserine or cystathionine. In contrast, the metF- and metH-disrupted mutants could not grow in the minimal medium contg. homocysteine. These results suggest that in T. thermophilus, homoserine is directly converted to homocysteine via O-acetylhomoserine and that homocysteine is methylated to synthesize methionine.

REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 80 HCAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2000:763256 HCAPLUS

DOCUMENT NUMBER: 134:40298

TITLE: Defects in methylthioadenosine phosphorylase are

associated with but not responsible for methionine-dependent tumor cell growth

Cancer Research (2000), 60(19), 5543-5547

AUTHOR(S): Tang, Baiqing; Li, Yunan N.; Kruger, Warren D. CORPORATE SOURCE: Division of Population Science, Fox Chase Cancer

ORPORATE SOURCE: Division of Population Science, Fox Chase Ca Center, Philadelphia, PA, 19111, USA

CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal LANGUAGE: English

SOURCE:

A large proportion of human tumor-derived cell lines and primary tumor cells show methionine-dependent growth. This phenomenon refers to the ability of cells to grow in media contg. methionine and the inability of cells to grow in media supplemented with methionine's precursor, homocysteine (Hcy). Methionine can be formed by two different pathways, the recycling pathway and the salvage pathway. To discover the basis for methionine-dependent growth, the authors have analyzed 12 tumor cell lines and 2 non-tumor-derived cell lines for defects in two key genes in different methionine synthetic pathways. The authors found little evidence that defects in methionine synthase expression or mutations in the MS gene are correlated with methionine-dependent growth. However, the authors did find a correlation between methionine-dependent growth and defects in expression of methylthioadenosine phosphorylase (MTAP), a key enzyme in the salvage pathway. Three of the four cell lines lacking detectable MTAP protein were unable to grow in Hcy-contg. media, whereas all six of the MTAP-pos. cell lines tested showed strong growth. However, when the authors introduced MTAP cDNA into MTAP-deficient MCF-7 cells, the resulting cell line was still defective in growth on Hcy, although it

could now grow on the salvage pathway precursor methylthioadenosine. These findings indicate that salvage pathway defects are not causally related to methionine-dependent growth.

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 80 HCAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2000:753687 HCAPLUS

DOCUMENT NUMBER: 134:205650

TITLE: Molecular biology of methionine synthase:

Interrelationships with homocysteine and vascular

disease

AUTHOR(S): Banerjee, Ruma

CORPORATE SOURCE: Biochemistry Department, University of Nebraska,

Lincoln, NE, 68588-0664, USA

SOURCE: Developments in Cardiovascular Medicine (2000

), 230, 291-311

CODEN: DCMEDM; ISSN: 0166-9842
PUBLISHER: Kluwer Academic Publishers
DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review, with 66 refs. Methionine synthase is one of

two key enzymes that manages cellular homocysteine and is found in most mammalian tissues. It catalyzes the B12-dependent transmethylation of homocysteine using methyltetrahydrofolate as a Me group donor. The

cDNA encoding human methionine synthase has

been cloned recently and its sequence has been detd. Catastrophic mutations in methionine synthase are found in the cblG class of patients, and are correlated with severe hyperhomocysteinemia with attendant cardiovascular diseases. However, polymorphisms have yet to be found that are correlated with the moderate hyperhomocysteinemia. A mouse knock out of the methionine synthase gene

confers an embryonic lethal phenotype, indicating that it is an essential gene. The activity of methionine synthase is also

dependent on redox proteins that reactivate oxidized enzyme. The components of this redox pathway have been described recently to be a cytochrome P450-like methionine synthase reductase and

sol. cytochrome b5. Mutations in methionine synthase

reductase have been identified in the cblE class of patients and are correlated with severe hyperhomocysteinemia.

REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 80 HCAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2000:728565 HCAPLUS

DOCUMENT NUMBER: 134:261672

TITLE: MET15 as a visual selection marker for Candida

albicans

AUTHOR(S): Viaene, Jasmine; Tiels, Petra; Logghe, Marc; Dewaele,

Sylviane; Martinet, Wim; Contreras, Roland

CORPORATE SOURCE: Department of Molecular Biology, Unit of Fundamental

and Applied Molecular Biology, University of Ghent and Flanders Interuniversity Institute for Biotechnology,

Ghent, B-9000, Belg.

SOURCE: Yeast (2000), 16(13), 1205-1215

CODEN: YESTE3; ISSN: 0749-503X

PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE: Journal LANGUÄGE: English

AB To develop better mol. genetic tools for the diploid yeast Candida albicans, the suitability of the MET15 gene as a visual selection marker was studied. Both MET15 alleles of C. albicans CAI-4 were isolated by functional complementation of a Saccharomyces cerevisiae strain lacking the MET15 gene. Growth of this complemented strain on Pb2+-contg. medium was assocd. with a color shift of brown into white colonies. The MET15 alleles of C. albicans were located on chromosome 4 by pulsed-field gel electrophoresis and Southern blotting. A met15-deficient strain of C.

albicans CAI-4 was generated using the ura blaster technique. This strain showed a brown colony color on Pb2+-contg. medium, which corresponded with the colony color of a S. cerevisiae strain lacking the MET15 gene. Unexpectedly, the met15-deficient strain of C. albicans still grew on methionine-depleted medium. However, this growth was severely delayed. In addn., complementation of this strain with an integrative or replicative plasmid contg. either of the MET15 alleles resulted in the formation of white transformants on Pb2+-contg. medium. These transformants grew very well on methionine-depleted medium. Colony sectoring was obtained with the replicative plasmid and not with the integrative one. This study demonstrates that the MET15 gene of C. albicans is suitable as a visual marker and therefore can be used to identify transformants and study plasmid stability.

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 80 HCAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2000:709207 HCAPLUS

DOCUMENT NUMBER: 134:160885

TITLE: Genetic modulation of homocysteinemia

AUTHOR(S): Rozen, Rima

CORPORATE SOURCE: Departments of Human Genetics, Pediatrics, and

Biology, McGill University, Montreal Children's

Hospital, Montreal, Can.

SOURCE: Seminars in Thrombosis and Hemostasis (2000

), 26(3), 255-261

CODEN: STHMBV; ISSN: 0094-6176 Thieme Medical Publishers, Inc.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

PUBLISHER:

A review with 57 refs. With the identification of hyperhomocysteinemia as a risk factor for cardiovascular disease, an understanding of the genetic determinants of plasma homocysteine is important for prevention and treatment. It has been known for some time that homocystinuria, a rare inborn error of metab., can be due to genetic mutations that severely disrupt homocysteine metab. A more recent development is the finding that milder, but more common, genetic mutations in the same enzymes might also contribute to an elevation in plasma homocysteine. The best example of this concept is a missense mutation (alanine to valine) at base pair (bp) 677 of methylenetetrahydrofolate reductase (MTHFR), the enzyme that provides the folate deriv. for conversion of homocysteine to methionine. This mutation results in mild hyperhomocysteinemia, primarily when folate levels are low, providing a rationale (folate supplementation) for overcoming the genetic deficiency. Addnl. genetic variants in MTHFR and in other enzymes of homocysteine metab. are being identified as the cDNAs/genes become isolated. These variants include a glutamate to alanine mutation (bp 1298) in MTHFR, an aspartate to glycine mutation (bp 2756) in methionine synthase, and an isoleucine to methionine mutation (bp 66) in methionine synthase reductase. These variants have been identified relatively recently; therefore addnl. investigations are required to det. their clin. significance with respect to mild hyperhomocysteinemia and vascular disease.

REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 80 HCAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2000:590906 HCAPLUS

DOCUMENT NUMBER: 133:279864

TITLE: The Allele Frequency of Mutations in Four Genes that

Confer Enhanced Susceptibility to Venous

Thromboembolism in an Unselected Group of New York

State Newborns

AUTHOR(S): Conroy, J. M.; Trivedi, G.; Sovd, T.; Caggana, M. CORPORATE SOURCE: P.O. Box 509, Wadsworth Center, Division of Genetic

Disorders, Molecular Genetic Epidemiology Laboratory,

New York State Department of Health, Albany, NY,

12201-0509, USA

3OURCE: Thromb. Res. (2000), 99(4), 317-324

CODEN: THBRAA; ISSN: 0049-3848

Elsevier Science Inc.

DOCUMENT TYPE: Journal LANGUAGE: English

PUBLISHER:

AB The frequencies of Factor V G1691A (FV Leiden, FVL), prothrombin (PT) G20210A, 5',10'-methylenetetrahydrofolate reductase (MTHFR) C677T, and

methionine synthase (MS) A2756G (four mutations assocd. with an increased risk of venous thromboembolism [VTE]) were detd. in a sample of approx. 1500 New York State residents. Dried blood spots from approx. equal nos. of Caucasians, African-Americans and Hispanics were anonymously obtained from the New York State Department of Health Newborn Screening Program. Following PCR amplification of dried blood spot DNA, allele-specific oligonucleotide hybridization was used to detect mutant alleles. The total no. of individuals at increased genetic risk for VTE was 271 (17.5%) of the 1553 persons tested. Increased genetic risk was defined as the heterozygous state for FVL or PT and the homozygous state for the MTHFR or MS polymorphisms. Sixteen individuals had more than one genetic risk factor. The MS gene variant allele frequencies for African-Americans and Hispanics are the first to be reported. This report also provides an est. of the variant PT allele in the largest group of Hispanics studied to date.

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 80 HCAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2000:493687 HCAPLUS

DOCUMENT NUMBER: 133:115929

TITLE: Human methionine synthase

reductase and cDNA and methods for

evaluating risk of neural tube defects, cardiovascular

disease, cancer, and Down's syndrome

INVENTOR(S): Gravel, Roy A.; Rozen, Rima; Leclerc, Daniel; Wilson,

Aaron; Rosenblatt, David McGill University, Can. PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT ASSIGNEE(S):

SOURCE:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000042196	A2	20000720	WO 2000-IB209	20000114 <
WO 2000042196	A.3	20010125		

W: CA, JP

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.:

US 1999-232028 A 19990115 US 1999-371347 A 19990810

AB The invention features a novel cDNA encoding methionine synthase reductase. The invention also features a method for detecting an increased likelihood of hyperhomocysteinemia and, in turn, an increased or decreased likelihood of neural tube defects, cardiovascular disease, Down's Syndrome or cancer. The invention also features therapeutic methods for treating and/or reducing the risk of cardiovascular disease, Down's Syndrome, cancer, or neural tube defects. Also provided are the sequences of the human methionine synthase reductase gene and protein and compds. and kits for performing the methods of the invention. Thus, the cDNA for human methionine synthase reductase was cloned and sequenced. Northern blots indicated that the methionine synthase reductase gene was expressed to some degree in all tissues but is particularly abundant in skeletal muscle. In addn. to a 3.6 kb band, a 3.1 kb and a faint 6 kb band were detected in brain mRNA.

The methionine synthase reductase gene was mapped to human chromosome 5p15.2-p15.3. Two deletion mutations were found in cblE patients: one resulted in deletion of Ile-576, the other resulted in a frameshift and premature truncation. Two polymorphisms were also detected: a G/A polymorphism at nucleotide 66 resulting in either Ile or Met at position 22 and a second G/A polymorphism at nucleotide 110 resulting in Tyr or Cys at position 37. Correlation of methionine synthase reductase gene mutations and risk for neural tube defects, Down's syndrome, and premature coronary artery disease was examd.

```
=> \s \ 9033-23-2/rn
             1 9033-23-2/RN
~ L1
 => d
 L1
     ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
      9033-23-2 REGISTRY
 RN
 CN
      Methyltransferase, methyltetrahydrofolate-homocysteine (9CI) (CA INDEX
      NAME)
 OTHER NAMES:
      Cobalamin-dependent methionine synthase
 CN
 CN
      E.C. 2.1.1.13
 CN. Methionine synthase
 CN
     Methionine synthetase
     Methyltetrahydrofolate-homocysteine methyltransferase
 CN
 CN
     Methyltetrahydrofolate-homocysteine vitamin B12 methyltransferase
 CN
      N-Methyltetrahydrofolate:L-homocysteine methyltransferase
 CN
      N5-Methyltetrahydrofolate methyltransferase
 CN
      N5-Methyltetrahydrofolate-homocysteine methyltransferase
 CN
      N5-Methyltetrahydrofolic-homocysteine vitamin B12 transmethylase
 CN
      Tetrahydrofolate methyltransferase
 CN
      Tetrahydropteroylglutamate methyltransferase
 CN
      Tetrahydropteroylglutamic methyltransferase
 CN
      Vitamin B12 methyltransferase
MF
      Unspecified
 CI
     MAN
 LC
      STN Files:
                   ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,
        CA, CAPLUS, CEN, CIN, EMBASE, PROMT, TOXCENTER, USPATFULL
 *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
```

ا جئ

444 REFERENCES IN FILE CA (1967 TO DATE) 445 REFERENCES IN FILE CAPLUS (1967 TO DATE)

NiceZyme View of ENZYME: EC 2.1.1.13

Official Name				
5-methyltetrahydrofolatehomocysteine S-methyltransferase.				
Alternative Name(s)	Alternative Name(s)			
Methionine synthase. Tetrahydropteroylglutama	Methionine synthase. Tetrahydropteroylglutamate methyltransferase.			
Reaction catalysed				
5-methyltetrahydrofolate + L-homocysteine <=> tetrahydrofolate + L-methionine				
Cofactor(s)				
Cobalamin.				
Comments				
 Acts on monoglutamate or triglutamate derivatives. The bacterial enzyme requires S-adenosyl-L-methionine and reduced FAD. 				
Cross-References				
BRENDA 2.1.1.13				
EMP/PUMA	2.1.1.13			
WIT	2.1.1.13			
KYOTO UNIVERSITY LIGAND CHEMICAL DATABASE	2.1.1.13			
IUBMB Enzyme Nomenclature	2.1.1.13			
MEDLINE	Find literature relating to 2.1.1.13			
SWISS-PROT	Q09582, METH_CAEEL; P13009, METH_ECOLI; Q99707, METH_HUMAN; Q49775, METH_MYCLE; O33259, METH_MYCTU; O33465, METH_PSEPU; P37586, METH_SALTY; Q55786, METH_SYNY3;			

View entry in original ENZYME format

If you would like to retrieve all the SWISS-PROT entries referenced in this entry, click here.

ExPASy Home page	Site Map	Search ExPASy	Contact us	ENZYME